Evidence map›Paper›PMID 41647786›Full record

ArticleESMO real world data and digital oncology2024

Real-world behavioral practices of cancer patients: misconceptions compromising daily life activities.

E Shachar, S Peleg-Hasson, D Vorobiof, N Moisa, E Waller, T Safra, I Wolf

Abstract read
In one paragraph

Article in ESMO real world data and digital oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

E ShacharFaculty of Medicine, Tel Aviv University, Tel Aviv.
S Peleg-HassonFaculty of Medicine, Tel Aviv University, Tel Aviv.
D VorobiofBelong.life, Tel Aviv, Israel.
N MoisaBelong.life, Tel Aviv, Israel.
E WallerFaculty of Medicine, Tel Aviv University, Tel Aviv.
T SafraFaculty of Medicine, Tel Aviv University, Tel Aviv.
I WolfFaculty of Medicine, Tel Aviv University, Tel Aviv.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Health-related quality of life is commonly used as an endpoint in clinical trials. While it evaluates the presence of symptoms, it does not measure patients' ability to maintain normal daily life activities (DLA). We designed a daily life assessment tool, validated among actively treated cancer patients at a single center before the coronavirus 2019 pandemic. We discovered that most patients reported compromised daily activities. In this study we aimed to examine DLA in an international cohort. Methods: A locally validated questionnaire was distributed internationally using the Belong.life digital health platform. We examined real-world patient-reported practices. The survey consisted of demographic, clinical, behavioral parameters and sources guiding and supporting patient practices. Results: The study comprised 1395 patient-reported outcomes. The majority of participants (1005, 73%) reported at least one adopted limitation in daily activities, and 305 (22%) maintained more than half of these constraints. Daily life restrictions included avoiding sun exposure (779, 58%), international travel (417, 33%), indoor public places (431, 33%), hair dyeing (271, 23%), domestic tourism (284, 22%), contact with friends and family (231, 18%), children and grandchildren (202, 16%), public spaces (190, 14.62%), and contact with pets (135, 10%). Multiple sources were implicated by patients guiding their behavior, including healthcare professionals (951, 66%), non-medical authorities [(internet, patient forums, partners, friends, and family (171, 12%)], and both non-medical authorities and the healthcare team (320, 22.19%). There was no association between country of origin ( Conclusion: The majority of patients globally reported compromised daily activities, which are likely attributed to misconceptions about therapy and disease. These findings call for the assessment of an overlooked measure, DLA reflecting real-life quality of life, as an additional endpoint of clinical trials, aiming to achieve the ultimate benefit for our patients, a measure of a full and meaningful life.

Indexed as

behaviorcancerdaily-life activitieshealth-related quality of lifepatient-reported outcomesrestrictions

Identifiers

PMID41647786
PMCPMC12836787

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.